Figure 3: Overall survival reported for similar patients treated with radioembolization, sorafenib and placebo. 90Y-radioembolization: consecutive patients identified with Child-Pugh class A and advanced stage disease (BCLC stage C) or had intermediate stage disease (BCLC stage B) and had failed prior vascular procedures (TACE; TAE) or were poor candidates for TACE [29]. Sorafenib (SHARP): patients randomized to the sorafenib arm in the SHARP trial [42]. Sorafenib (US phase II): patients with Child-Pugh class A class that received sorafenib in the US phase II study [46]. Placebo (SHARP): patients randomized to the placebo arm in the SHARP trial [42].